<DOC>
	<DOCNO>NCT00977561</DOCNO>
	<brief_summary>This study summarize safety patient receive figitumumab combine etoposide cisplatin ( carboplatin ) vs. patient receive etoposide cisplatin ( carboplatin ) alone first line treatment extensive stage disease Small Cell Lung Cancer .</brief_summary>
	<brief_title>A Study Of Cisplatin ( Or Carboplatin ) And Etoposide With Or Without Figitumumab ( CP-751,871 ) In Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>The study prematurely discontinue January 26 , 2011 due slow enrollment . It note safety concern see study factor decision .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm diagnosis extensive stage disease Small Cell Lung Cancer ( SCLC ) , tumor biopsy sample require . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Total IGF1 &gt; = 120 ng/ml Any prior systemic therapy Small Cell Lung Cancer ( SCLC ) HbA1c &gt; = 5.7 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Small Cell Lung Cancer</keyword>
	<keyword>Extensive stage disease</keyword>
	<keyword>SCLC</keyword>
	<keyword>IGF-1R inhibitor</keyword>
</DOC>